Effect Of Intestinal Resection On Quality Of Life In Crohn's Disease

Wright EK1, Kamm MA2, De Cruz P1, Hamilton AL1, Ritchie KJ1, Krejany EO1, Gorelik A1, Liew D1, Prideaux L1, Lawrance IC1, Andrews JM1, Bampton PA1, Sparrow MP1, Florin TH1, Gibson PR1, Debinski H1, Gearry RB1, Macrae FA1, Leong RW1, Kronborg I1, Radford-Smith G1, Selby W1, Johnston MJ1, Woods R1, Elliott PR1, Bell SJ1, Brown SJ1, Connell WR1, Desmond PV1. J Crohns Colitis. 2015 Apr 8. pii: jjv058. [Epub ahead of print]

INTRODUCTION: Patients with Crohn's disease have poorer health related quality of life (HRQoL) than healthy individuals, even when in remission. Although HRQoL improves in patients who achieve drug induced or surgically induced remission, the effects of surgery overall have not been well characterised.

METHODS: In a randomised trial patients undergoing intestinal resection of all macroscopically diseased bowel were treated with post-operative drug therapy to prevent disease recurrence. All patients were followed prospectively for 18 months. CRP, CDAI and faecal calprotectin (FC) were measured pre-operatively and at 6, 12 and 18 months. HRQoL was assessed with a general (SF36) and disease-specific (IBDQ) questionnaires at the same time points.

RESULTS: 174 patients were included. HRQoL was poor pre-operatively but improved significantly (p<0.001) at 6 months post-operatively. This improvement was sustained at 18 months. Females and smokers had a poorer HRQoL when compared to males and non-smokers respectively. Persistent endoscopic remission, intensification of drug treatment at 6 months and anti-TNF therapy were not associated with different HRQoL outcomes than if these factors were not present. There was a significant inverse correlation between CDAI, but not endoscopic recurrence, CRP or FC, on HRQoL.

CONCLUSION: Intestinal resection of all macroscopic Crohn's disease in patients treated with post-operative prophylactic drug therapy is associated with significant and sustained improvement in HRQoL irrespective of type of drug treatment or endoscopic recurrence. HRQoL is lower in female patients and smokers. A higher CDAI, but not direct measures of active disease or type of drug therapy, is associated with a lower HRQoL.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.